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Abstract
Background: The protection, which some BCG vaccines could confer against the development
of tuberculosis (TB) in childhood, might be indirectly reflected by the subsequent development of
BCG immune response. The objectives of the study were to examine effectiveness and possible
differences of post-vaccination reaction to a lyophilized BCG at different age groups and to evaluate
its protection against TB in a decade's period.
Methods:  We studied the post-vaccination PPD-skin reaction and scar formation at three
different school levels, corresponding to ages of 6, 12 and 15 years old, vaccinated by a lyophilized
BCG vaccine (Pasteur Institute), currently used in our country. During a 10-year follow up the
reported TB cases in vaccinated and non-vaccinated adolescences up to 24-years old were analyzed
and compared to the number of cumulative cases observed in the adult population of two
neighboring territories (vaccinated and non-vaccinated).
Results and Discussion: There was a significant correlation (r2 = 0.87, p < 0.0001) between
tuberculin induration and scar formation. There was no statistically significant difference between
the three age groups (6, 12, and 15 year-old, respectively) in regard to the diameter of tuberculin
induration or scar formation. Although 34% of 10-year later indurations were unpredictably related
to the initial ones (increased or decreased), they were significantly correlated (r2 = 0.45, p = 0.009).
The relative percentage of TB for the 14–24 years-age group to the adult studied population was
significantly lower among the immunized children compared to the non-immunized population of
the same age group (17/77, 22% vs. 71/101, 70%, p < .0001).
Conclusion: Our data suggest that the lyophilized BCG vaccine used for BCG programs at
different age groups is equally effective and may confer satisfactory protection against tuberculosis
in puberty.
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Background
As one third of the world's population is already infected
with mycobacterium tuberculosis (TB), efficacious con-
trol of TB, one of the world's major health threats, is best
achieved by a combination of chemotherapy and vaccina-
tion. Bacillus Calmette-Guerin (BCG) vaccination is com-
pulsory in 64 countries and recommended in others [1].
Recently, the World Health Organization expanded pro-
grams of immunization recommended BCG at 3 months
[2], while in many areas there is vaccination at birth [3],
at school entry and in adolescence [4]. The policy in
Greece for some years has been to recommend BCG vacci-
nation routinely in schools to children aged 11 to 13
years, but adjusted to a current tuberculous infection
index of 3.4%, this schedule has been recently endorsed
by offering the vaccine at school entry (ages 5 to 7 years),
until the risk of infection is low everywhere in Greece. The
justification for continuing vaccination throughout the
country even although TB is now rarely encountered in
some areas, is related to the mobility of the population:
many young people study, join the army, or seek work in
areas where TB is more prevalent [5].
The efficacy of BCG vaccination, however, has been
strongly questioned [6]. Studies in older children and
adults showed 77% protection in Britain [7]), only 14%
in southern USA [8], and none in Madras [9]. Further-
more, in a retrospective study of 22 children with TB of
the spine in a developing country, all gave a history of
BCG vaccination scars [11]. In addition, several reports
recommending the continuation of the policy of BCG vac-
cination offered routinely in schools, are now concerned
about the influence of the quality of the vaccine, its trans-
portation, and the technique of its application on the pro-
tection obtained [10]. Laxity in the TB control
programmes and widespread of HIV could also appear to
have a role in the recent reurgence of TB infection world-
wide [11]. However, methodological and statistical reap-
praisal has showed that different biological and
environmental conditions in individual studies and, prin-
cipally, biases or inadequate statistical power may have
contributed to the conflicting data [12]. Recently, findings
at 15 years showed that even among populations with
high infection rates and high non-specific sensitivity
where BCG did not offer any protection against adult
forms of bacillary pulmonary tuberculosis, BCG offered
some level of overall protection (up to 50%) in children
[13].
BCG induced tuberculin sensitivity is a quantitative char-
acteristic and has been used to compare vaccine efficacy.
It has been also suggested that the protection which some
BCG vaccines could confer against the development of TB
in childhood, might be indirectly reflected by the subse-
quent development of BCG immune response [14,15].
The preliminary research, however, has been restricted to
examine the effectiveness of freeze dried vaccines only,
and has not been extended to study the immunologic
properties of the lyophilized BCG vaccines, currently used
in Europe. Furthermore, those limited studies were prop-
erly oriented to evaluate the protective effect of BCG in
either infant Asians or high risk neonates, thus including
too few details to permit assessment of the main clinical
expressions of acquired immunity and to draw the indis-
putable conclusions about the significance and its derived
implications among the general population.
As part of a prospective assessment of the efficacy of a
lyophilized BCG vaccine used in current BCG schemes in
Greece, we had the opportunity to evaluate its immuno-
logic response to study the interrelations between the
post-vaccination tuberculin sensitivity and scar forma-
tion, and to analyze their epidemiological data in children
who had received BCG in three different age groups. Dur-
ing the next decade, we comparatively recorded the 10-
year reported TB cases in vaccinated and non-vaccinated
adolescents up to 24-years old in our territory and in a
neighboring area not covered by similar preventive pro-
gram, and compared them to the 10-year number of
cumulative cases observed in the adult population of the
two areas.
Methods
Participants
Intradermal BCG vaccination has been offered routinely
to schoolchildren living in the district area covered by our
health center since 1988 and continues up to date. Chil-
dren participating in the preventive program from 1/10/
1988 to 1/10/1993 were enrolled in the study. To restrict
escapes, BCG scheme was annually applied at three differ-
ent school levels, corresponding to ages of about 6, 12 and
15 years old, respectively. All children monitored in each
of the cohorts were documented to be receiving their first
BCG vaccination when they were in their respective age
groups and had not previously been vaccinated (there is
no neonatal BCG program in Greece and also all children
should have had negative tuberculin testing before been
enrolled in the study). Children, who had received BCG
vaccination at birth or at any other time because of known
contact with a case of TB, were excluded from the study.
Likewise, notified subjects given chemoprophylaxis,
whether tuberculin positive or negative, were also
excluded from analysis. Of a total of 1,124 vaccinated
schoolchildren included in the final analysis (group A),
394 received their first vaccination at age 6 and accord-
ingly were classified in the 6 year -old group, 483 in the 12
year-old first vaccination group and 247 in the 15 year-old
first vaccination group.Journal of Immune Based Therapies and Vaccines 2005, 3:1 http://www.jibtherapies.com/content/3/1/1
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Methodology
Vaccine was given by a doctor and team of health visitors
experienced in vaccination technique. Lyophilized vac-
cine (0,1 ml, Pasteur inst.) was injected intra-dermaly over
the insertion of the left deltoid muscle to produce a weal
of about 7-mm diameter, using a separate syringe and a
27-G needle for each person [10]. The reconstituted vac-
cine used at our center contains about 0.15 mg moist
weight of Galmette-Guerin organisms per ml, which
implies a concentration of colony-forming units of viable
organisms of 6 × 106/ml. In all cases using 10 UI of PPD
was performed three days before vaccination along with a
thorough clinical examination. Tuberculin testing was
repeated three months after vaccination when children
were again reviewed. The result was read three days later
and induration of 6 mm or more, when read across the
forearm, was regarded as positive result [14]; induration
of 4–5.9 mm as a weak positive and induration less than
4 mm as a PPD-negative. Scar formation was classified as
real scar (>2 mm), tiny (≤ 2 mm), or not visible [10]. No
other immunologic studies were done to correlate immu-
nity to BCG with assessment of other in vitro responses to
vaccination, since in such a massive program it would not
be feasible to do many things in many individuals in a
short time, especially, in a school environment. As the
study did not affect patient care, the institutional review
board waived the need for informed parental consent.
Sub cohorts
Those who gave a negative result retested within one
month. In proved tuberculin negative responders (Man-
toux < 4 mm), revaccination was suggested and if consent
was obtained, the vaccine was given apart from the site of
the scar of the previous BCG vaccination (group R) as it
was previously advised [10].
Controls
Children in schools not participating in the BCG prophy-
laxis program (schools in neighboring areas not covered
by our health center) were used as controls for the follow
up period (non vaccinated adolescences). In total 1340
control children of comparative age groups were recorded
the same time period. The two territories had similar pop-
ulation according to the latest data (2001) available by
the National Statistics Center (vaccinated 375024 and
non-vaccinated 348236).
Follow-up
Tuberculin testing was repeated ten years after vaccination
in a small proportion of children, still attending school
and if an informed parental consent had previously been
obtained. Also, during the intervened decade, we compar-
atively recorded the 10-year reported TB cases in vacci-
nated and non-vaccinated adolescents from more than 14
up to 24-years old in the two territories. Data were drawn
from the Health Centre's records and the National Statis-
tics Center of Infectious Diseases, and subsequently were
analyzed and compared to the 10-year number of cumu-
lative cases observed in the adult population (more than
25 years old) in the same areas (vaccination area covered
by our health center and non-vaccinated neighboring area
not covered by our health center). There were not any epi-
demiologic data available regarding the incidence of TB in
the 6 up to 14-year age group.
Statistical analysis
Methods for assessing data significance included the two-
sample null hypothesis for a two-tailed test, the Mann-
Whitney U test and the x2 test with Yates' correction, using
a standard statistical package.
Results
Tolerability
In all subjects tuberculin testing before vaccination gave a
negative result and on the basis of history or clinical
examination there was no contraindication to perform
BCG vaccination. The procedure was well tolerated with
no cases of osteopathy and only very few of reactions such
as, three cases of transient lymphadenopathy and one of
local subcutaneous abscess.
Age groups
Details of tuberculin testing and scar formation at each
age group are shown in Figures 1 and 2. There was no sta-
tistically significant difference between the three age
groups (6, 12, and 15 year-old, respectively) in regard to
the diameter of tuberculin induration or scar formation.
The mean (SD) diameter of the tuberculin reaction was
11.13 (4.20) mm. The distribution of Mantoux indura-
tion diameters appeared to be the one of normal curve
with the 95% confidence limits set at 2.73 mm and 19.53
mm (binomial distribution). Extensive search revealed no
evidence of active TB in those schoolchildren with a tuber-
culin induration greater than or equal to 20 mm.
Although 1034 (92.2%) subjects gave a positive post-vac-
cination tuberculin reaction, 45 (4%) gave a weak positive
induration, and 43 (3.8%) gave a PPD-negative test. Real
scar formation has been developed in 96% of the vacci-
nated schoolchildren and a tiny scar (≤ 2 mm) in 3.5%.
Tuberculin induration and scar formation
There was a significant correlation (r2 = 0.87, p < 0.0001)
between tuberculin induration and scar formation (Figure
3). Table 1 shows that none of the children without scar
formation has developed PPD-positive reaction. Instead,
99.4% of the children with positive tuberculin skin testing
exhibited scar formation compared to only 39.5% of
those who were negative for tuberculin reactivity (p <
0.001). Accordingly, the possibility for a schoolchild to
not develop a visible scar has been significantly higherJournal of Immune Based Therapies and Vaccines 2005, 3:1 http://www.jibtherapies.com/content/3/1/1
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Post-vaccination tuberculin testing in three school-age groups Figure 1
Post-vaccination tuberculin testing in three school-age groups
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among Mantoux negative children than among those who
presented with either a positive Mantoux (p < 0.001), or a
weak positive tuberculin testing (p < 0.001). The real esti-
mated percentage of the possibility for absence of scar for-
mation in Mantoux negative children has been included
between the 95% limits of 14% and 38%, the most possi-
ble value been an estimated percentage of 23 % (binomial
distribution).
Tuberculin negative subjects were more likely to develop
a tiny scar than the subjects with a positive (p < 0.001) or
weak positive Mantoux test (p < 0.025), respectively.
There has been a higher percentage of tiny scars in chil-
dren with tuberculin indurations of 4–5,9 mm than in
those with the next range (6–9 mm) of induration diam-
eters (p < 0.001). The real estimated percentage for the
presence of a tiny scar in children with a tuberculin reac-
tion of less than 6 mm has been included between the
95% limits 42% to 54% (mean 47%, binomial
distribution)]
Negative reactors
Of the 43 tuberculin negative reactors, 32 cases were
reviewed. Lack of reactivity was confirmed and all 32 had
the BCG vaccine repeated. Surprisingly, following revacci-
nation, reactivity levels to 10 UI of PPD (90.6%) were
similar to the reactivity rates documented in the initial
vaccination group A cohort (92.2%, NS), corresponding
to 100% scar formation. There was not only an apparently
similar distribution of tuberculin indurations (p < 0.42),
but also a similar mean between groups (group R 12.76
(5.40) mm vs. 11.13 (4.20) mm for group A, p = 0.1).
Follow-up
A. Tuberculin induration
Ten years later the cohorts became inconsistent and many
children disappeared (studies, army, new families) or –
when found – most denied having a repeated Mantoux
test. Among 183 16-year old schoolchildren (former 6
year -old group) been visited by health visitors at schools
in 2005, 110 denied to participate in the follow-up of the
BCG scar formation in three school-age groups Figure 2
BCG scar formation in three school-age groups
2 18
374
3 15
465
1 6
240
0
50
100
150
200
250
300
350
400
450
500
not visible tiny (<2) real (>2)
Scar Formation (mm)
N
u
m
b
e
r
o
f
c
h
i
l
d
r
e
n
(
n
)
6-year-old children (n=394)
12-year-old children (n=483)
15-year-old children (n=247)Journal of Immune Based Therapies and Vaccines 2005, 3:1 http://www.jibtherapies.com/content/3/1/1
Page 6 of 12
(page number not for citation purposes)
Correlation between tuberculin induration and scar formation Figure 3
Correlation between tuberculin induration and scar formation
Table 1: No (%) of BCG scar formations in three groups of different post vaccination tuberculin reactions among school children
Mantoux Children Evaluation of scar formation [n (%)]
Induration (mm) n Real scar (>2 mm) Tiny scar (≤ 2 mm) No scar (?)
Negative (0–3,9) 43 17 (39.5)* 20 (46.5)**,*** 6 (14)***,***
Weak positive (4–5,9) 45 32 (71.1) 13 (28.9)**,*** 0 (0)***,***
Positive (>6) 1036 1030 (99.4)* 6 (0.6)***,*** 0 (0)***,***
Total 1124 1079 (96.0) 39 (3.5) 6 (0.5)
p values apply to differences among negative, weak positive and positive indurations for the same scar formation groups (real scar, tiny or not visible 
scar).
* < 0.01, ** p < 0.025, *** p < 0.001.
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study. Thus, approximately 10 years later (2005), we only
managed to repeat Mantoux in 73 children of the 6 year-
old group of the 1993–5 year period. There was no
statistically significant difference between the two year
periods in regard to the diameter of tuberculin indura-
tions (mean (SD) diameter of the tuberculin reaction 8.4
(5) mm in 2005 vs. 8.1 (6) mm in 1995). The mean
paired difference of the paired samples test was non sig-
nificant: .25 (6) mm (95% confidence interval of the dif-
ference: lower: -1.9, upper: 2.4 mm). Although the paired
sample correlation (Figure 4) was significant (r2 .45, p =
0.009) and new individual values were almost identical to
the old ones in 66% of children (± 2 mm), a great propor-
tion of the 10-year later values were unpredictably related
(12% decreased, 22% increased) to the initial ones (Fig-
ure 5).
B. TB cases
Data available in the National Statistics Center of Infec-
tious Diseases and in the Health Centre's records showed
that the TB cases recorded among vaccinated adolescents
– more than 14 up to 24 years-old – during the last decade
in our territory were lower compared to the non-vacci-
nated adolescents (17 vs. 71 cases, in a decade). These
numbers would have resulted in the wrong estimation of
1.3% vs. 6.3% TB incidence in adolescenthood for the
Paired sample correlation (quadratic regression) of tuberculin indurations between the two time – periods (initial study period  and 10-year later follow up) Figure 4
Paired sample correlation (quadratic regression) of tuberculin indurations between the two time – periods (initial study period 
and 10-year later follow up)
Mantoux 1995 (mm)
30 20 10 0 -10
M
a
n
t
o
u
x
2
0
0
5
(
m
m
)
20
10
0
-10Journal of Immune Based Therapies and Vaccines 2005, 3:1 http://www.jibtherapies.com/content/3/1/1
Page 8 of 12
(page number not for citation purposes)
vaccinated schoolchildren and controls, p < 0.0001, if
they had only been restricted to the studied population.
However, the recorded TB cases were extended to a
decade's population, including at least three times more
similarly treated children in each group, making therefore
statistical analysis impossible. The numbers of the
recorded TB cases for the adult population (>25 years old)
in the two territories recorded during the same period
were slightly lower for the vaccinated area compared to
non-vaccinated territory (77 vs. 101 cases). Thus, the rela-
tive percentage of TB for the 14–24 years-age group to the
responded adult population, which could provide us with
the only comparable numbers, was significantly lower
among the immunized children (17/77*100) compared
to the non-immunized population (71/101*100) of the
same age group (22% vs. 70% of all ages, x2 = 14.7, p <
0.0001).
Discussion
Because of the conflicting results of major controlled tri-
als, BCG vaccination against TB remains controversial
despite more than 50 years of use. The wide range of BCG
protective efficacy values reported by the trials extended
from 75%, reflecting substantial protection by the vaccine
[3] to negative ones indicating a higher rate of TB among
vaccinees than controls [16].
Although the tuberculin state after vaccination was not
generally thought to influence the degree of protection
offered by BCG, children who did not become sensitive to
tuberculin either died subsequently of disseminated TB
[17] or developed tuberculous meningitis [18]. Further-
more, the relative increase of TB in the mainly unimmu-
nized cohorts born in a European country after 1975,
compared with the mainly BCG immunized cohorts born
there in the period 1969–1974 was, by the end of 1984,
estimated at 6 (95% confidence interval, 2.3 to 16.1) [19].
Subsequently, when a high level of post-vaccination
immune response was achieved, the estimated protective
efficacy for the vaccine was shown to be 64% with 95%
confidence limits of 43% and 77% and the prevented frac-
tion 0.50 [15].
Conflicting results from two centers in the United King-
dom showed that only 45–46% of vaccinated children
were Mantoux positive when tested between the ages of 3
Follow up of recent individual indurations (2005) correlated to initial Mantoux values (10-year time interval) Figure 5
Follow up of recent individual indurations (2005) correlated to initial Mantoux values (10-year time interval)
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months and 2 years [20]; 25% had no visible scar [21].
Another study carried out in a third center, however,
showed that 353 (98%) out of 361 Asian neonates given
BCG were tuberculin positive when tested three months
later [14]. Tuberculin conversion rates of 93% or 88%
were also established following BCG vaccine in 15 term
and 8 pre-term infants, respectively [22]. In addition, a
more recent study among 193 Asian vaccinees revealed a
positive post-vaccination tuberculin testing in 184 of
them (95%) [15]; these results are consistent with those of
the present study confirming a 94% prevalence of
immune response to BCG in a sample of 1124 vaccinated
Greek schoolchildren. If impaired immunity was the
cause of diminished tuberculin sensitivity after vaccina-
tion, then a fairly constant proportion of Asian or Greek
children would be expected to be non-reactors to tubercu-
lin after vaccination. In another study, significantly higher
proportions of infants given Japanese BCG were found to
be tuberculin convertors (74.7%) when compared to
those given British BCG (51.4%). In our study groups
there was no difference between initially or repeatedly
vaccinated children (92% vs. 90%), and this was also
reflected in the frequency of non-visible scar formations.
In the negative reactors, however, BCG vaccination could
have triggered protective (Lister type) rather than
antagonistic (tuberculin or Koch type) reactions, which
have been speculated to be the most protective [23].
Similar to other study findings done in infants [24], we
also did not observe any significant difference in mean
tuberculin reaction, tuberculin positivity and mean scar
size according to different age group at administration.
Results of our study confirm a highly positive correlation
between scar formation and post vaccination tuberculin
sensitivity among schoolchildren at various ages. This
finding is remarkably similar to that suggested by reports
in India and the United States, which have shown that the
size of the BCG scar was associated with considerable
enhancement in sensitization to tuberculin [25,26]. Simi-
larly, in a recent study the prevalence of skin test positivity
was also consistently higher among individuals compared
to those without a BCG scar [27]. Our data confirm this
trend, since children who failed to produce a BCG scar did
not have evidence of a positive post-vaccination immune
response to tuberculin skin testing. It's important to note
however that negative skin test reactivity can still be asso-
ciated with real (46.5%) or tiny scar (39.5%) formation
(37 or 43 patients, total 86%). It must be also noticed that
in contrast to most previous studies, this study uses a
lyophilized vaccine, demonstrating the basic characteris-
tics of a recently used BCG vaccination in a western coun-
try upon the entry of the new millennium.
The 1079 subjects with a scar are assumed to have
mounted an initial response to the vaccination, as
reflected by a strong positive immune response in the
1030 of them (99.4%). Possibly, a few negative or weak
responses were due to physiological implications such as
general health nutritional status, prevalence and espe-
cially virulence of atypical mycobacteria [23], an infection
with  M. Kansasii approximating 80% of the potential
protection offered by BCG [28]. Furthermore, in a popu-
lation with a low level of sensitivity to PPD (median skin
reactions 3 mm), 36% of the subjects gave a greater
response to an atypical antigen such as PPD-B [29]. It is
unlikely, however, that all negative results were caused by
this, since most of the Mantoux negative children turned
to become positive reactors after they subsequently under-
went repeat BCG vaccination. This finding which has been
further enhanced by an observed similar to the expected,
according to our results, distribution of tuberculin indura-
tions, is in agreement with recent reports, suggesting that
revaccination resulted in a significant increase in positiv-
ity to tuberculin 10 and to other reagents tested [30].
Accordingly, it seems unlikely that the impaired reaction
to tuberculin in some of the recently vaccinated subjects
had been caused by a defect of initial recognition of the
antigen or an inability to retain this information or even
by a failure of sensitized lymphocytes to react because the
individual was malnourished or had a serious infection
[23]. Instead, there is circumstantial evidence that even
when given at birth, BCG achieves tuberculin conversion
in a high proportion of neonates [31], irrespective of race
[32], ethnic origin [33] or prematurity [24]. Since age has
not been a significant factor in influencing BCG immune
response in the present study, the age mass vaccine must
be offered at should be ideally adjusted to the one, shortly
before the infection rate is going to be accelerated [6].
Although the mean (SD) diameter of postvaccination
tuberculin reactors in our study was unexpectedly high,
(11.13 (4.20) mm), this was significantly lower than a
mean of 17.9 mm calculated for naturally infected sub-
jects [33,34] and was not significantly different from the
mean postvaccination reaction of 9.4 (2.7) mm reported
by others [15]. Surprisingly, also, a much wider distribu-
tion range of tuberculin indurations has been included
between the 95% confidence limits for the sample (2.73–
19.53 mm). In fact, a 71.1% of those with a weak positive
Mantoux (4–5.9 mm) exhibited a scar of >2 mm, which
has been previously suggested to adequately represent a
positive immune response to BCG vaccination [35]. The
rest of them (28.9%) exhibited a tiny BCG scar, presuma-
bly underlining a rather smoother and wider transition
zone between PPD positive and negative reactions. Exam-
ining two different batches of new tuberculin, Stanford JL
and Tala-Heikkila found that the mean size of the BCG
scar was 8.1 (SD 4.8) mm, and there was a trend associat-
ing smaller BCG scars with smaller tuberculin responses,Journal of Immune Based Therapies and Vaccines 2005, 3:1 http://www.jibtherapies.com/content/3/1/1
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which did not reach statistical significance [36]. Although
such an explanation for the right end of the curve appears
to be in disagreement with the assumption that reactions
larger than 10 mm in diameter are likely to represent
infection [30], a similar wide transition zone for variable
positive reactions is also strongly supported in our study
by the demonstration of a previous negative PPD testing,
immediately followed by the BCG vaccination which has
been shortly preceded the tuberculin inversion. Thus, the
large tuberculin reaction achieved in a substantial propor-
tion of children shortly after BCG might simply represent
a strong cell-mediated immune response among individ-
ualized expressions of recently acquired immunity.
Besides, BCG vaccination at birth and for school age chil-
dren causes reactivity to tuberculin which persists for 20
to 25 years, so that an induration diameter of > 15 mm
does not exclude a vaccinal origin [37]. Similarly, in our
study among schoolchildren, no significant waning of
immunity to BCG was shown 10 years after initial vacci-
nation. We also showed that although the immune
response to BCG persisted for so long, individual
responses varied widely (increased or decreased) in 1/3 of
children, the meaning of which couldn't be extrapolated.
In a recent study, prior BCG vaccination had a strong
influence on skin test results of <or = 18 mm in diameter
among persons <40 years old, compared with the influ-
ence of factors predictive of M. tuberculosis infection [38].
For vaccinated subjects with a previous negative tubercu-
lin test, it is also necessary to exclude the booster effect.
Thus, according to our results and those of others [39], an
induration diameter of > 15 mm does not exclude a vacci-
nal origin [38]. Additionally, in some cases, such a reac-
tion might also suggest that sensitization to mycobacteria
species might have occurred at a very young age. Although
such a sensitization might not be detected by the tubercu-
lin test, it can influence response to BCG vaccination [40].
The marked difference of tuberculin reaction rate between
Indian towns strongly supports such an influence of expo-
sure to mycobacteria in the environment [27]. Although it
has been found that in a population with a high level of
sensitivity to PPD (median skin reaction 12 mm), only
7% of the subjects tested gave a greater response to an
atypical antigen than to PPD [31], determination of the
optimum range of reactions to the BCG vaccination in a
given population is a more contentious issue, which can-
not be fully resolved without further information about
the interactions among the quality of vaccine, the time
elapsed, the prevalence and virulence of atypical myco-
bacteria, the booster effect, the immunologic memory and
the mechanisms of its responsiveness to other reagents
[40]. It is therefore not possible in the late post-vaccina-
tion period to distinguish between a tuberculin reaction
caused by virulent supra-infection and one resulted from
persistent post-vaccination sensitivity, even in the case of
a strong positive reaction to 10 UI of tuberculin PPD.
Repeat BCG vaccination, malnutrition, and BCG with
scars present difficulties in making a diagnosis of TB but
did not affect PPD reactivity and did highlight the need
for thorough clinical evaluation [41]. Although, high
tuberculin sensitivity in healthy schoolchildren may be
partially maintained by contact with environmental
mycobacteria, attributing a 'positive' Mantoux response to
past BCG vaccination may be encouraging a false sense of
security in contacts recently exposed to an infectious case
of TB. Our results confirm the general assumption that the
major disadvantage of BCG is that it clouds interpretation
of the tuberculin skin test [42]. These results, however, do
also suggest that the notification of post-vaccination
tuberculin induration diameter about 3 months after
BCG, might well be served as a self-control measurement
in the case of clinical diagnosis of TB [43], since post-vac-
cination skin reactions tend usually to decrease with time.
Additional factors, such as age of the contact and sputum
status of the index case are important determinants of the
degree of increased tuberculin sensitivity [44]. However,
at the rise of the millennium, new blood assays (QuantiF-
ERON-TB, CSL Limited), which measure gamma inter-
feron production when M. tuberculosis-specific proteins,
such as the ESAT-6, are incubated with venous blood sam-
ples, are promising for the recognition of infection with
Mycobacterium tuberculosis, since they are not influ-
enced by past BCG exposure [45].
Although vaccination does not prevent the establishment
of infection in someone exposed to tubercle bacilli, its
effect does limit the multiplication and dissemination of
tubercle bacilli and the development of lesions after infec-
tion. The direct effect of BCG vaccination is defined as pre-
vention of TB in vaccinated persons and the indirect as the
reduction of TB in the population as a whole [30]. Results
of epidemiological research laboratories, however,
showed considerable variation in the current BCG vacci-
nation policy in different districts while the population is
highly mobile [37]. To allow the proportion of unvacci-
nated young people to increase while more than 3,420
new sputum positive cases of TB are reported annually in
Greece – now much more increased among AIDS victims
-increases the risk of disease, which may well not be diag-
nosed until others have been infected [46].
Since there is evidence in the neonatal period, but not in
childhood, challenging the view that sensitization is
essential for protection [47], the assumption that a posi-
tive skin test following vaccination is an indicator of BCG-
induced immunity against Mycobacterium tuberculosis
might not have been a correct one. We thought, however,
that because a high rate of PPD skin test conversion
following BCG vaccination in schoolchildren and its per-
sistent reactivity for 10 years might both increase the
degree of protection offered by BCG, it should beJournal of Immune Based Therapies and Vaccines 2005, 3:1 http://www.jibtherapies.com/content/3/1/1
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concluded that the particular lyophilized BCG vaccine
used for BCG programs in Greek schools may confer sat-
isfactory protection against TB in puberty. Our results are
further enhanced by the findings of a recent study, which
showed that BCG vaccination at birth and for school age
children causes reactivity to tuberculin which persists for
20 to 25 years [48]. The recorded decline of TB among the
adolescents in the vaccinated area, highlights the need to
sustain and, wherever possible, intensify preventive and
case finding measures in all groups at special risk [49], but
it might also suggest that the continuation of offering
mass BCG vaccination should ideally be maintained eve-
rywhere, including regions that currently have a low prev-
alence of TB [5]. Similarly, in view of the current incidence
of TB in Finland and the likelihood that lymph node
infections and sensitivity to environmental mycobacteria
will increase, continued BCG vaccination at birth has
been recommended [37].
One of the main limitations of this study is that the sam-
ple size for a comparison of disease occurrence between
the study and control groups was too small and thus sta-
tistically underpowered for such an analysis. Furthermore,
it wouldn't be practically possible to follow up and record
disease occurrence in the cohorts, since there was no
computerised system importing data from hospitals or
insurance agencies into the health centre and patients do
not often reveal such medical confidentialities by them-
selves. Accordingly, since we had covered all schools at
three different age-levels in our territory, and there was
not any BCG program running in the control territory, we
made the logical assumption that vaccination was wide-
spread in our territory, and absent in the other. A severe
limitation of this hypothesis, however, is the prerequisite
of a second assumption that no significant migration and
no significant differences in the prevalence of latent TB
infection or the proportion of adult cases with positive
sputum smear, must have occurred over the study period.
For all these reasons, the prevention part of this study is
not so strong and has accordingly not been the primary
endpoint of the study. Another limitation of the study is
that we did not succeed in following all cohorts further,
retesting them some years later to assess age-related differ-
ences that may have been substantial in terms of waning
responses. Children of the 12 and 15 year-old cohorts had
finished school, the cohorts became inconsistent, and
even when personal data were still available (addresses,
phones) it was found extremely difficult to bring people
back to the health centre. The response of the retested
patients, however, might offer a realistic idea of what reac-
tion could have been found in the other age groups as
well.
Continuation of the BCG programs could easily work as a
bridge to the coming era of new generation of TB vaccines.
It has been already shown that vaccination with ESAT-6
antigen from mycobacterium tuberculosis, which is a
dominant target for cell-mediated immunity in the early
phase of tuberculosis, delivered in a combination of
monophosphoryl lipid A and dimethyl dioctadecylam-
monium bromide, which are adjuvant efficients for the
induction of cellular and humoral immune responses,
elicited a strong ESAT-6-specific T-cell response and pro-
tective immunity comparable to that achieved with myco-
bacterium bovis BCG [50]. As one third of the world's
population is already infected with Mycobacterium tuber-
culosis and because the acquired immune response is
mediated by different T-cell sets, two types of vaccine may
be required: one for eradication of already established
infection and the other for prompt combat of invading
microbes [51]. Meanwhile, emphasis should especially be
placed on the importance of the quality, transportation
and preservation of the vaccine and on the technique of
application [10], that may be responsible for the widely
divergent results of prospective BCG trials in several coun-
tries, that have lead to current doubts about the efficacy of
BCG vaccination in TB prevention.
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